BioInvent International AB · OMXSTO:BINV
BioInvent International AB — CORD Communication, Stockholm (September 2019)
21 slides from BioInvent International AB's conference presentation, Sep 25, 2019
Slide 1: Company Presentation
COMPANY PRESENTATION September 25 2019 1
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB (“BioInvent”). Neither shall the presentation or any
Slide 3: Company Snapshot
COMPANY SNAPSHOT LEADING ANTIBODY IMMUNO-ONCOLOGY PLATFORM ▪ Advancing Cancer Immunotherapy by overcoming tumor resistance ✓ ▪ Validated by publications in top-tier journals e.g. Cancer Cell, and Immunity and partnerships with leading pharma companies such as Pfizer, Transgene, Bayer Pharma, Daiichi
Slide 4: Events in the Second Quarter and After the Reporting Period
EVENTS IN THE SECOND QUARTER ▪ Publication of first data from two parallel Phase l/lla clinical trials of BI-1206. ▪ €0.75 million milestone payment from Mitsubishi Tanabe Pharma Corporation in connection with enrollment of the first patient in a Phase II clinical trial of an antibody identified fro
Slide 5: F.I.R.S.T - A Unique Patient Centric Platform for Discovery of Novel Oncology Targets
s F.I.R.S.T™- A UNIQUE PATIENT CENTRIC PLATFORM FOR DISCOVERY OF NOVEL ONCOLOGY TARGETS AND MAB Bioinvent’s proprietary platform Clinically relevant targets & monoclonal antibody (mAb) Platform validated by Pfizer - Pfizer is now using the platform for their tumor associated myeloid cells (TAM) 5
Slide 6: New Drugs and Mechanisms Are Needed to Improve Cancer Immunotherapy & Survival
s NEW DRUGS AND MECHANISMS ARE NEEDED TO IMPROVE CANCER IMMUNOTHERAPY & SURVIVAL THE CONCEPT ONLY A SUBSET OF A RAPIDLY WORKS PATIENTS GROWING MARKET RESPOND TO 2016 sales 1 CURRENT DRUGS 43bn (USD) New drugs direct the New mechanisms and immune system to antibodies needed to 2022E sales1 combat tum
Slide 7: BioInvent Targets Key Immune Suppressive Cells & Mechanisms to Boost Anti-Cancer Immunity
s BIOINVENT TARGETS KEY IMMUNE SUPPRESSIVE CELLS & MECHANISMS TO BOOST ANTI-CANCER IMMUNITY The cancer immunity cycle 4 Trafficking of T cells to tumors Priming and activation (CTLs) 3 -+ of T cells Tregs1 (CD25+ foxp3+) TAM2/MDSC3 CTL4 Macrophages5 Infiltration of T cells into 5 tumors Cancer antig
Slide 8: Pipeline – Multiple Value Drivers
PIPELINE – MULTIPLE VALUE DRIVERS Indication Program Discovery Preclinical Phase I Phase II Target: FcγRIIB NHL (MCL, MZL, iFL) BI-1206 / rituximab Solid cancer BI-1206/ pembrolizumab Solid cancer BI-1607 2019 Target: Tumor associated regulatory T cells (Tregs) Solid cancer αCTLA-4-GM-CSF-VV 2020 So
Slide 9: FcgRIIB – A Single Inhibitory Antibody Checkpoint to Unlock Anti-Cancer Immunity
FcgRIIB – A SINGLE INHIBITORY ANTIBODY CHECKPOINT TO UNLOCK ANTI-CANCER IMMUNITY Antibody checkpoints T cell checkpoints Innate immunity Adaptive immunity Part of the immune system that kills tumor Activates Part of the immune that eliminates the pathogens cells, but also activates and shapes the an
Slide 10: BI-1206 in Non-Hodgkin Lymphoma Turbocharging Anti-CD20
BI-1206 IN NON-HODGKIN LYMPHOMA TURBOCHARGING ANTI-CD20 ▪ Rituximab is effective when bound The immune cells fails to attack the tumor cell to CD20 on the cell surface, but its efficacy is hampered by FcgRIIB- mediated endocytosis ▪ Rituximab is a monoclonal antibody PRE BI-1206 (Rituxan®, Mabthera®
Slide 11: BI-1206: Cutting Both Ways
BI-1206: CUTTING BOTH WAYS BI-1206 BLOCKS RITUXIMAB INTERNALIZATION AND IMPROVES ITS ANTI-TUMOR ACTIVITY Human CD20 FcγRIIB double transgenic mice Humanized model of relapsed / refractory CLL1 B cell depletion in vivo BOOSTING RITUXIMAB’S EFFECT OVERCOMING RESISTANCE % objective responders (blue) Co
Slide 12: BI-1206: Expanding Therapeutic Potential - Phase I/IIa Study
BI-1206: EXPANDING THERAPEUTIC POTENTIAL - PHASE I/IIA STUDY STUDY OVERVIEW − A multicenter, open label, Phase I/IIa study in relapsed or refractory indolent Non-Hodgkin Lymphoma (iNHL) patients enriched with Mantle Cell Lymphoma – approximately 24 patients across sites in US & EU − High proportion
Slide 13: BI-1206: Value Proposition – Key Segments & Value Drivers
BI-1206: VALUE PROPOSTION – KEY SEGMENTS & VALUE DRIVERS KEY SUB-SEGMENTS OF NON-HODGKIN LYMPHOMA (NHL) Value drivers Safety, chemo-free regimen and scientific rationale in anti-CD20 refractory B-cell lymphoma are key drivers of BI-1206 attractiveness. ▪ First-in-class in hematology - no direct comp
Slide 14: 18-BI-1206-03 Clinical Study in Solid Tumors
18-BI-1206-03 Clinical Study in Solid Tumors STUDY OVERVIEW − A multicenter, open label, Phase I/IIa study in adults with advanced solid tumors who have relapsed or are refractory to anti- PD-1 or anti-PD-L1 therapy– approximately 60-70 patients across sites in US & SWE − High unmet medical need – d
Slide 15: Targeting Tregs and TAMs to Mitigate Immune Suppression
TARGETING TREGS AND TAMS TO MITIGATE IMMUNE SUPPRESSION ▪ Regulatory T cells (Tregs) can Developing antibodies that act on Tregs via novel or validated targets substantially inhibit immune responses, enabling tumor cells to 1. 2. 3. TARGETING TREGS escape detection. ▪ BioInvent is utilizing its F.I.
Slide 16: MAbs + Oncolytic Virus to Target Solid Tumors
MABS + ONCOLYTIC VIRUS TO TARGET SOLID TUMORS 50/50 PARTNERSHIP WITH TRANSGENE TO DEVELOP NEXT GENERATION ONCOLYCTIC VIRUS MAbs and oncolytic virus attacking the solid tumor ABOUT THE COLLABORATION BioInvent’s CTLA-4 mAB ▪ BioInvent and Transgene collaborate to co-develop oncolytic virus (OV) candid
Slide 17: Pipeline – Multiple Value Drivers
PIPELINE – MULTIPLE VALUE DRIVERS Indication Program Discovery Preclinical Phase I Phase II Target: FcγRIIB NHL (MCL, MZL, iFL) BI-1206 / rituximab Solid cancer BI-1206/ pembrolizumab Solid cancer BI-1607 2019 Target: Tumor associated regulatory T cells (Tregs) Solid cancer αCTLA-4-GM-CSF-VV 2020 So
Slide 18: Key Milestones
KEY MILESTONES TIMING EVENTS ✓ Start Phase I/IIa BI-1206/rituximab combination trial in NHL H2 2018 ✓ Preclinical rationale Anti-CTLA-4/oncolytic virus, SITC Poster ✓ BI-1206 /rituximab orphan drug designation (ODD) in mantle cell lymphoma ✓ Podium Presentation SLAS 2019 Washington on F.I.R.S.T tm H
Slide 19: Proprietary Manufacturing Platform Since 1988
PROPRIETARY MANUFACTURING PLATFORM SINCE 1988 ▪ Supports fast and flexible production of proprietary programs ▪ State of the art single use bioreactor (SUB) technology: 40L -1,000L batch sizes ▪ Approved for Phase l to lll production ▪ Track record of 30 years inspections ▪ Consistent source of near
Slide 20: Management Team
MANAGEMENT TEAM Martin Welschof Björn Frendéus Andres McAllister Chief Executive Officer Chief Scientific Officer Chief Medical Officer Holdings: 125,000 shares Holdings: 483,083 shares; 270,258 options Holdings: 91,656 options Ph.D. (Dr.rer.nat.) in recombinant antibody technology. Post-doctoral Do
Slide 21: Board of Directors
BOARD OF DIRECTORS Leonard Kruimer An van Es Johansson Dharminder Chahal Chairman Board member Board member Holdings: - Holdings: 76,120 shares Holdings: 2,587,733 shares MBA. Provides presently interim management solutions and consulting M.D. VP and Head of Medical Affairs at Swedish Orphan Biovitr
BioInvent International — CORD Communication, Stockholm (September 2019) on 6ix